UP CHO - 10 September 2021
Pharmacology
Easy

WHO's ______ assesses the quality, safety and efficacy of Covid-19 vaccines and is a prerequisite for COVAX Facility vaccine supply.

Appeared in: UP CHO - 10 September 2021

Explanation

  • The WHO's Emergency Use Listing (EUL) is the specific pathway designed to accelerate the availability of new or unlicensed medical products during public health emergencies.
  • This procedure involves a rigorous assessment of safety, efficacy, and manufacturing quality data from late-stage clinical trials.
  • Successful EUL is a mandatory prerequisite for vaccines to be procured and supplied through the COVAX Facility, a global initiative for equitable vaccine access.
  • The term 'emergency-use authorization' was widely used during the pandemic, making 'Emergency Use Listing' the correct official terminology in this context.

Why Other Options Were Wrong

  • Option A: This is a broad, general category of pharmaceuticals. It is not the name of a specific regulatory pathway or list maintained by the WHO for emergency vaccine assessment.
  • Option B: This is a descriptive phrase, not the official name of the WHO's assessment process. The EUL procedure evaluates overall quality, safety, and efficacy, not just efficiency.
  • Option C: This is a plausible-sounding but incorrect term designed to be a distractor. The official name uses 'Emergency Use', not 'Emergent Utility'.

Related Visual

Visual explanation — Related Visual
Clinical Relevance
  • Nursing practice connection: This is primarily an exam-oriented knowledge point with limited direct bedside application, so retain WHO's Emergency Use Listing (EUL) procedure for vaccines as background academic context rather than a clinical decision trigger.
  • Nurses are central to administering vaccines approved under EUL and must be prepared to educate patients about the vaccine's benefits and potential side effects, addressing any concerns about the accelerated approval process.
  • A key nursing responsibility is the vigilant monitoring, identification, and prompt reporting of any Adverse Events Following Immunization (AEFI) through established channels, which is critical for the ongoing safety surveillance of these new vaccines.
  • What if a patient is hesitant to receive a vaccine because it only has an 'emergency' listing? The nurse can explain that EUL is a rigorous WHO process based on strong clinical trial evidence for safety and effectiveness, designed specifically for public health crises.
How to Approach the Question
  • First, identify the core subject of the question: a specific WHO procedure for approving COVID-19 vaccines for the COVAX program.
  • Note the keywords: 'WHO', 'assesses quality, safety, efficacy', and 'prerequisite for COVAX'. This points to a formal, regulatory process.
  • Evaluate the options. 'Life Saving Drugs' is too general. 'Listing of Highly Efficient Vaccine' is a descriptive phrase, not an official title.
  • You are left with two similar-sounding options: 'Emergent Utility List' and 'Emergency Use Listing'.
  • Recall the terminology widely used during the pandemic. Health authorities like the FDA used 'Emergency Use Authorization (EUA)'. This makes 'Emergency Use Listing (EUL)' the most likely correct term for the WHO's parallel process.
  • Select 'Emergency Use Listing' as it aligns with established terminology for accelerated approvals during public health crises.
Concept Tested & Keywords
  • Concept Tested: WHO's Emergency Use Listing (EUL) procedure for vaccines
  • Stem keywords: WHO, Covid-19 vaccines, COVAX Facility, quality, safety, efficacy
  • Lead-in keywords: assesses

Question ID

QITjz171d1-r8wPLV5DCcq

Reference Book

E6 Pharmacology KD Tripathi Essentials 9e Part 3 p. 290-292

E6 Robert Boland, Marcia L. Verduin - Kaplan and Sadock's Comprehensive Text of Psychiatry-Wolters Kluwer Health (2024) (pp 1-16525 of 16525) p. 11137-11139

Practise the full UP CHO - 10 September 2021

Attempt every question from this paper in a timed mock, then review the full solution for each one.